Earlier work by Harris et al. [9], demonstrated that a particular HER2+ tumor phenotype overexpressing genes associated with the basal-like phenotype, including higher expression of basal cytokeratins (CKs), was more frequent in the non-responding group of patients receiving pre-operative trastuzumab than in the responding group. The gene discussed is ERBB2; the disease is neoplasm.